Many tumors have more than one genetic abnormality and researchers want to be able to identify them all at once. Having multiple targets for therapies could help circumvent the drug resistance that often develops during cancer treatment. New research suggests that this approach may be possible—in a pilot study of nine people, the researchers identified genetic changes more comprehensively by comparing tumor DNA to normal DNA from the same person. The researchers also compared the activity of tumor genes to that of normal genes. Next, they hope to speed the DNA sequencing turnaround time and to optimize the process for verifying treatment targets in tumor biopsies.